A Phase 1 interventional study of STN1012600 ophthalmic solution 0.002% in Healthy Adult Males Volunteers, sponsored by Santen Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to male participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-05.
Sponsored by Santen Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
To evaluate the safety and plasma pharmacokinetics of STN1012600 ophthalmic solution 0.002% (1 drop once daily for 7 days) in healthy adult male subjects.
Exclusion Criteria:
Drug: STN1012600 ophthalmic solution 0.002%
1 drop STN1012600 ophthalmic solution 0.002% once daily for 7 days
Maximum Plasma Concentration [Cmax]
Calculate plasma pharmacokinetic parameters and study pharmacokinetics.
Time frame: 1 week, Day 1 and Day 7
Area Under The Curve From Time Zero to the Last Sampling Time [AUC 0-t]
Calculate plasma pharmacokinetic parameters and study pharmacokinetics.
Time frame: 1 week, Day 1 and Day 7
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Santen Pharmaceutical Co., Ltd.